A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation.
Definitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows.
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.